(Circulation. 2000;102:2058.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Epidemiological and Genetic Associations of Activated Factor XII Concentration With Factor VII Activity, Fibrinopeptide A Concentration, and Risk of Coronary Heart Disease in Men
From the Department of Medicine, University College London Medical School, Rayne Institute, London, UK (F.Z., F.D., S.E.H.); MRC Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, Charterhouse Square, London, UK (S.R.B., G.J.M.); Biometrics Department, Pfizer Central Research, Sandwich, Kent, UK (S.R.B.); Nuffield Department of Clinical Biochemistry, University of Oxford, Radcliffe Infirmary, Oxford, UK (M.P.E.); and Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City (J.H.M.).
Correspondence to G.J. Miller, MD, FRCP, MRC Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, Charterhouse Square, London EC1M 6BQ. E-mail g.miller{at}mds.qmw.ac.uk
Background—The relations of plasma activated factor XII (FXIIa) concentration and a common polymorphism (C46T) of the factor XII gene with hemostatic status and risk of coronary heart disease (CHD) were examined by prospective surveillance.
Methods and Results—Genotyping for the C46T variant was performed in 2624 men 50 to 61 years of age who were free of CHD at baseline. The genotype distribution was as follows: CC, 56.7%; CT; 36.9%; and TT, 6.6%. Plasma FXIIa was measured by ELISA on 1745 samples collected 1 year after baseline; median levels were (ng/mL) CC, 2.0; CT, 1.4; and TT, 0.8 (P<0.0001). Respective values for plasma fibrinopeptide A (FPA, nmol/L) were 1.52, 1.35, and 1.15 (P<0.0001); for factor VII coagulant activity (FVIIc, % standard), 114.5, 116.2, and 109.3 (P=0.02). Group differences in FVIIc were unchanged by adjustment for body mass index and serum triglycerides. Whereas CHD incidence did not differ significantly by genotype, rates (per 1000 person-years) by thirds of FXIIa distribution were for <1.5 ng/mL, 7.2; for 1.5 to 2.0 ng/mL, 7.2; and for >2.0 ng/mL, 13.6. Respective hazard ratios with the low third as reference group were 1.01 and 1.96 (P=0.007), which were essentially unchanged after allowance for genotype, blood lipids, blood pressure, body mass index, FVIIc, and FPA.
Conclusions—The C46T polymorphism is a determinant of FXIIa, FPA, and possibly FVIIc, suggesting that FXII influences the activity state of the coagulation pathway and FPA cleavage from fibrinogen in vivo. Plasma FXIIa is increased in middle-aged men at high risk of CHD.
Key Words: coronary disease • genes • coagulation • epidemiology
This article has been cited by other articles:
 |
|
 |
|
  M. Y. Chan, F. Andreotti, and R. C. Becker Hypercoagulable States in Cardiovascular Disease Circulation, November 25, 2008; 118(22): 2286 - 2297. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gailani and T. Renne Intrinsic Pathway of Coagulation and Arterial Thrombosis Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2507 - 2513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Sanders, F. Lewis, S. Slaughter, B. A Griffin, M. Griffin, I. Davies, D J. Millward, J. A Cooper, and G. J Miller Effect of varying the ratio of n-6 to n-3 fatty acids by increasing the dietary intake of {alpha}-linolenic acid, eicosapentaenoic and docosahexaenoic acid, or both on fibrinogen and clotting factors VII and XII in persons aged 45-70 y: the OPTILIP Study. Am. J. Clinical Nutrition, September 1, 2006; 84(3): 513 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Renne, M. Pozgajova, S. Gruner, K. Schuh, H.-U. Pauer, P. Burfeind, D. Gailani, and B. Nieswandt Defective thrombus formation in mice lacking coagulation factor XII J. Exp. Med., July 18, 2005; 202(2): 271 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Santamaria, J. Mateo, I. Tirado, A. Oliver, R. Belvis, J. Marti-Fabregas, R. Felices, J. M. Soria, J. C. Souto, and J. Fontcuberta Homozygosity of the T Allele of the 46 C->T Polymorphism in the F12 Gene Is a Risk Factor for Ischemic Stroke in the Spanish Population Stroke, August 1, 2004; 35(8): 1795 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Humphries, P. M. Ridker, and P. J. Talmud Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation? Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 628 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Papageorgiou, A. Pourdjabbar, A. A. Amfilochiadis, E. P. Diamandis, F. Boomsma, and D. H. Osmond Are cardiovascular and sympathoadrenal effects of human "new pressor protein" preparations attributable to human coagulation {beta}-FXIIa? Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H837 - H846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zitzmann, R. Junker, A. Kamischke, and E. Nieschlag Contraceptive Steroids Influence the Hemostatic Activation State in Healthy Men J Androl, July 1, 2002; 23(4): 503 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Klein, M. Spannagl, and B. Engelmann Phosphatidylethanolamine Participates in the Stimulation of the Contact System of Coagulation by Very-Low-Density Lipoproteins Arterioscler Thromb Vasc Biol, October 1, 2001; 21(10): 1695 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Orth, S. Westphal, J. Dierkes, C. Luley, and K. Schlatterer Rapid Factor XII (46C{->}T) Genotyping by Fluorescence Resonance Energy Transfer in Patients with Coronary Artery Disease or Thrombophilia Clin. Chem., June 1, 2001; 47(6): 1117 - 1119. [Full Text] [PDF]
|
|